Fanatics Collectibles to Open Its First-Ever Global Flagship Store in the Spring of 2025, to Be Located on Iconic Regent Street in London
22.1.2025 13:00:00 CET | Business Wire | Press release
The Much-Anticipated Interactive Store Will Focus on Sports and Entertainment Trading Cards, Offer Exclusive Product and Host Events, Athletes and ClubsIncluded in Its Unique Footprint: An In-Store Breaking Area, a State-of-the-Art Trading-Card Singles Experience, Card Opening and Trading Areas and Customer Education Touchpoints
Today Fanatics Collectibles announced its first-ever flagship store, to open in the spring of 2025 on iconic Regent Street in London. The focus: sports and entertainment trading cards and trading-card games, featuring Fanatics Collectibles’ brands, including Topps, Merlin, Match Attax and Bowman. Last year Topps secured the exclusive trading-card rights to the Premier League, with product launching in time for the 2025/2026 season. Topps also currently has the exclusive rights for UEFA national team competitions and club competitions and will begin making licensed NBA product later this year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250122281845/en/
(Photo: Fanatics Collectibles)
The much-anticipated store will span 803 square meters (8,647 square feet), and give collectors a one-of-a-kind experience seven days a week. The stunning visual centerpiece: a central display of the rarest and most-desirable cards, all with a giant suspended circular screen above. The flagship will offer exclusive product and have thousands of unique items, inclusive of single cards, retail boxes and high-end hobby releases. It will also see highly trafficked community-building events from monthly trade nights, kids rip events, athlete signings and appearances, partner activations and grading drop-off. Along with retail space, the store will feature a state-of-the-art breaking studio (live and taped opening of card packs), interactive customer education touchpoints – and a personal card creation suite.
“We are incredibly excited to cut the ribbon on this amazing community-building retail space, one that we hope will delight collectors and be a true home for the hobby in Europe,” said Topps President of Trading Cards, David Leiner. “It’ll be a destination for millions of fans as well as our own internal partners – and team and club partners, the latter using our dedicated space to launch and showcase new products in a way that has never been done before.” Speaking to internal partners, the new store will serve as a drop-off point for users of Fanatics Collect, a dynamic marketplace that connects buyers and sellers of trading cards. To the flagship being a home for fans and collectors, currently there are less than five Topps-partner hobby shops in the UK, and less than 30 in all of Europe. The annual footfall of south Regent Street is more than 70 million people.
While the store will focus primarily on trading cards, other items will be sold, including apparel (both Topps-branded and Fanatics-owned Mitchell & Ness) and memorabilia (signed kits, jerseys, balls and other equipment) and trading-card supplies. Types of trading-card products in the store: sports (soccer, football, baseball, F1, basketball, UFC, WWE), sports gaming cards (Match Attax) and entertainment (Disney, Marvel, Star Wars, Pixar, Garbage Pail Kids, Stranger Things).
About Fanatics Collectibles
Fanatics Collectibles is a new model and vision for the hobby fundamentally changing the experience for current and future collectors, leagues, and players across many professional and college sports. The organization secured long-term, exclusive rights to design, manufacture and distribute trading cards for several sports and entertainment properties, including MLB, MLBPA, the Premier League, MLS, UFC, Formula 1 as well as Disney, Marvel, Pixar and Star Wars, among others. In January 2022, Fanatics Collectibles announced the acquisition of Topps, establishing the preeminent licensed trading card brand as the cornerstone of Fanatics’ trading cards and collectibles business and jumpstarted its MLB and MLBPA rights to design, manufacture and distribute trading cards.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250122281845/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom